New Generic Approval: Methimazole Coated Tablets (ANADA 200-814)
Important Update for ACVP Members and Veterinary Pharmacy Professionals
The FDA has approved Methimazole Coated Tablets under ANADA 200-814, a generic equivalent to the pioneer product Felimazole® (NADA 141-292), for the treatment of hyperthyroidism in cats. This approval offers veterinary pharmacy professionals a reliable, cost-effective option for managing a common and progressive endocrine disorder in feline patients.
What Veterinary Pharmacists Should Know
1. FDA-Reviewed and Bioequivalent
Methimazole Coated Tablets (ANADA 200-814) have been reviewed by the FDA for bioequivalence to Felimazole. This ensures pharmacists and veterinarians can trust the new product to perform the same as the pioneer.
Important Note: The FDA advises that, unlike unapproved “generic” tablets marketed online, this product has undergone FDA review to verify safety and therapeutic equivalence. Pharmacy professionals should steer clients and clinics away from unapproved sources in favor of regulated, approved products.
2. Improved Compliance and Administration
The coated tablet formulation helps mask methimazole’s bitter taste, which is a known challenge in feline medication adherence. Availability in multiple strengths supports tailored dosing for individual patients.
Methimazole Coated Tablets are supplied in 2.5 mg and 5 mg for oral administration. Methimazole Coated Tablets are dosed in 2.5 mg increments, every 12 hours. Dose adjustments should be made in 2.5 mg increments. The maximum total dosage is 20 mg per day divided, not to exceed 10 mg as a single administration.
3. Safe Handling is Essential
Methimazole is an antithyroid agent that can be absorbed through the skin. ⚠️Anyone administering Methimazole Coated Tablets should wash their hands thoroughly with soap and water after handling⚠️ to prevent unintentional exposure. Pharmacists should educate clients and veterinary staff, particularly those who are pregnant, nursing, or have thyroid conditions, about safe administration practices.
4. Continued Monitoring is Necessary
While methimazole is effective in controlling hyperthyroidism, the disease may progress over time. Ongoing veterinary monitoring is essential to ensure the dose remains appropriate and to detect any changes in thyroid function or adverse effects. Pharmacists should remind clients and clinic teams of the importance of regular lab work and follow-up evaluations.
5. Compounding Considerations
With an FDA-approved coated tablet now available, routine compounding of methimazole is discouraged, except in cases where a specific strength or dosage form (e.g., transdermal) is medically necessary. Pharmacists should ensure compounding is in compliance with FDA guidance and based on individual patient need, not convenience.
Key Takeaway
The approval of Methimazole Coated Tablets (ANADA 200-814) represents a valuable advancement in feline endocrine care. Veterinary pharmacists are essential in:
- Promoting use of FDA-approved products over unregulated alternatives
- Providing education on safe handling and administration
- Supporting appropriate compounding practices
- Reinforcing the importance of ongoing veterinary monitoring for disease management
________________________________________
Final Thoughts
This new generic supports both cost-effective care and high-quality pharmaceutical standards in veterinary practice. As always, ACVP encourages its members to stay current on FDA announcements and practice evidence-based, compliant veterinary pharmacy.
For more information:
Final Thoughts
These approvals underscore the continued advancement of species-specific, FDA-reviewed therapeutics, and the essential role that veterinary pharmacists play in guiding ethical dispensing, regulatory compliance, and safe medication use.
As always, ACVP encourages its members to stay current on FDA announcements and practice evidence-based, compliant veterinary pharmacy.
